LAUSR

BACKGROUND Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. OBJECTIVE This study means to determine whether Mg supplementation improves glycemic control indicators in patients with T2D. METHODS After one week of the dietary stabilization phase, 42 T2D patients were stratified according to sex, age, fasting blood sugar (FBS) and Mg levels and then randomly allocated into two groups. The intervention group was on 250 mg/day of elemental Mg for three months while the control group did not receive any type of supplements throughout the intervention period. RESULTS The daily administration of 250 mg of elemental Mg indicated a significant improvement in HbA1C (8.32 to 7.96%, p < 0.001), insulin levels (IL) (15.56 to 12.18 μIU/mL, p < 0.001), C-peptide (2.28 to 1.90 ng/mL, p = 0.001), HOMA.IR (6.16 to 4.44, p < 0.001) and HOMA.β% (59.99 to 52.37, p = 0.036) of the intervention group when compared with the control group after three months of intervention. CONCLUSION The results of this study revealed that oral Mg supplementation reduces insulin resistance and improves the glycemic control indicators among T2D patients. TRIAL REGISTRATION current controlled trials PHRC/HC/32/15. Registered 5 October 2015.